[1] URIBE L,RONDEROS D M,DÍAZ M C, et al. Antisynthetase antibody syndrome:case report and review of the literature[J].Clin Rheumatol, 2013, 32(5):715-719. [2] LEE A Y S.A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity[J].Rheumatol Int, 2017, 37(8):1323-1333. [3] OKE V,WAHREN-HERLENIUS M.The immunobiology of Ro52(TRIM21) in autoimmunity:a critical review[J].J Autoimmun, 2012, 39(1/2):77-82. [4] SCHULTE-PELKUM J,FRITZLER M,MAHLER M. Latest update on the Ro/SS-A autoantibody system[J].Autoimmun Rev, 2009, 8(7):632-637. [5] PEENE I,MEHEUS L,DE KEYSER S, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease[J].Ann Rheum Dis, 2002, 61(10):929-933. [6] MARIE I,HATRON P Y,DOMINIQUE S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody[J].Semin Arthritis Rheum, 2012, 41(6):890-899. [7] LABRADOR-HORRILLO M,MARTÍNEZ M A,SELVA-O'CALLAGHAN A, et al. Identification of a novel myositis-associated antibody directed against cortactin[J].Autoimmun Rev, 2014, 13(10):1008-1012. [8] BETTERIDGE Z,MCHUGH N.Myositis-specific autoantibodies:an important tool to support diagnosis of myositis[J].J Int Med, 2016, 280(1):8-23. [9] SATOH M,TANAKA S,CERIBELLI A, et al. A comprehensive overview on myositis-specific antibodies:new and old biomarkers in idiopathic inflammatory myopathy[J].Clin Rev Allergy Immunol, 2017, 52(1):1-19. [10] RUTJES SA,VREE EGBERTS W T,JONGEN P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy[J].Clin Exp Immunol, 1997, 109(1):32-40. [11] FRANK M B,MCCUBBIN V,TRIEU E, et al. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies[J].J Autoimmun, 1999, 12(2):137-142. [12] 黄春梅,李永哲.多发性肌炎/皮肌炎自身抗体谱的研究进展[J].国际检验医学杂志,2006,27(1):33-35,39. [13] CHATTERJEE S,PRAYSON R,FARVER C. Antisynthetase syndrome:not just an inflammatory myopath[J].Cleve Clin J Med, 2013, 80(10):655-666. [14] MUMM G E,MCKOWN K M,BELL C L. Antisynthetase syndrome presenting as rheumatoid-like polyarthritis[J].J Clin Rheumatol, 2010, 16(7):307-312. [15] BAUHAMMER J,BLANK N,MAX R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome:anti-ro52 positivity as a marker for severity and treatment response[J]. J Rheumatol, 2016, 43(8):1566-1574. [16] SRIVASTAVA P,DWIVEDI S,MISRA R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis[J].Rheumatol Int, 2016, 36(7):935-943. [17] CRUELLAS M G,VIANA V D O S S,LEVY-NETO M, et al. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis[J].Clinics (Sao Paulo), 2013, 68(7):909-914. [18] ESPINOSA A,DARDALHON V,BRAUNER S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway[J].J Exp Med, 2009, 206(8):1661-1671. [19] SELVA-O'CALLAGHAN A,TRALLERO-ARAGUÁS E,GRAU-JUNYENT J M, et al. Malignancy and myositis:novel autoantibodies and new insights[J].Curr Opin Rheumatol, 2010, 22(6):627-632. [20] SCHMIDT J.Current classification and management of inflammatory myopathies[J].J Neuromuscul Dis, 2018, 5(2):109-129. |